QPL INT'L (00243) released its interim results, with a net profit attributable to shareholders of HK$77.895 million, a year-on-year increase of 591.79%.
QPL INT'L (00243) announced its interim performance for the six months ended on October 31, 2025. The company achieved a profit of HK$161 million, representing a 4.27% increase compared to the same period last year. The attributable net profit to the company's owners for the period was HK$77.895 million, a 591.79% increase year-on-year. Earnings per share were 24.62 HK cents.
QPL International (00243) released its interim performance for the 6-month period ending on October 31, 2025. The company achieved a profit of 161 million Hong Kong dollars, an increase of 4.27% compared to the previous year. The attributable net profit to the company's owners for the period was 77.895 million Hong Kong dollars, a 591.79% increase compared to the previous year. Earnings per share were 24.62 Hong Kong cents.
The announcement stated that during the period, fair value gain on financial assets recognized in profit or loss was approximately 60.31 million Hong Kong dollars, which had a positive impact on the group's financial performance. The fair value gain on financial assets recognized in profit or loss mainly included fair value gains on listed equity securities in CHINA JICHENG Limited, AMCO UNITED Limited, LUXXU GROUP Limited, and CH INV FIN GP Limited, amounting to approximately 34.20 million Hong Kong dollars, 11.00 million Hong Kong dollars, 4.30 million Hong Kong dollars, and 4.09 million Hong Kong dollars, respectively.
Related Articles

POLYFAIR HLDGS (08532) appoints Lu Lili as an independent non-executive director.

Geely Auto (00175) completes privatization of Jikitai.
3D MEDICINES(01244): ENVIDA is designated as an orphan drug for the treatment of gastric cancer and gastroesophageal junction cancer.
POLYFAIR HLDGS (08532) appoints Lu Lili as an independent non-executive director.

Geely Auto (00175) completes privatization of Jikitai.

3D MEDICINES(01244): ENVIDA is designated as an orphan drug for the treatment of gastric cancer and gastroesophageal junction cancer.





